Enliven Therapeutics, Inc.
Business
Enliven Therapeutics is a clinical-stage biopharmaceutical company discovering and developing small molecule therapeutics using a precision medicine approach targeting validated biological drivers. The company is advancing ELVN-001, a selective BCR-ABL tyrosine kinase inhibitor for chronic myeloid leukemia, through Phase 1 clinical trials. Enliven is also pursuing additional small molecule research programs in oncology and other indications such as Graves' disease, leveraging its team's expertise in medicinal chemistry and drug development. The company operates globally but does not manufacture products, relying on third-party contract manufacturing organizations.
Summary from 10-K filed 2026-03-03
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 86 | 81 | 65 | 31 | 38 | |
| General and administrative | 34 | 24 | 19 | 8 | 13 | |
| Total operating expenses | 120 | 105 | 84 | 39 | 51 | |
| Loss from operations | −120 | −105 | −84 | −39 | −51 | |
| Interest income | 16 | 15 | 12 | 1 | 233,000 | |
| Change in fair value of contingent value right liability | 0 | 873,000 | 0 | — | — | |
| Income tax expense | 0 | −232,000 | 0 | 88,000 | — | |
| Other expense | −49,000 | −2,000 | −22,000 | 0 | −175,000 | |
| Total other income (expense), net | 16 | 16 | 12 | 1 | 58,000 | |
| Net loss | −104 | −89 | −72 | −38 | −51 | |
| Net unrealized gains (losses) on marketable securities | 279,000 | −86,000 | 141,000 | 0 | −20,000 | |
| Comprehensive loss | −103 | −89 | −71 | −38 | −51 | |
| Net loss per share, basic | −1.83 | −1.89 | −2.01 | −12.05 | −2.37 | |
| Net loss per share, diluted | −1.83 | −1.89 | −2.01 | −12.05 | −2.37 | |
| Weighted-average shares outstanding, basic | 57 | 47 | 36 | 3 | 22 | |
| Weighted-average shares outstanding, diluted | 57 | 47 | 36 | 3 | 22 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2025 2025-01-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2023 2023-02-28 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 99 | — | 124 | 100 | — | |
| Marketable securities | 364 | — | 189 | 153 | — | |
| Restricted cash | 0 | — | 54,000 | 54,000 | — | |
| Prepaid expenses and other current assets | 12 | — | 5 | 3 | — | |
| Total current assets | 475 | — | 318 | 266 | — | |
| Property and equipment, net | 34,000 | — | 458,000 | 742,000 | — | |
| Operating lease right-of-use assets | 383,000 | 700,000 | 0 | 320,000 | — | |
| Deferred offering costs | 217,000 | — | 0 | 563,000 | — | |
| Other long-term assets | 656,000 | — | 7 | 4 | — | |
| Total assets | 476 | — | 326 | 272 | — | |
| Accounts payable | 2 | — | 1 | 532,000 | — | |
| Accrued expenses and other current liabilities | 14 | — | 15 | 15 | — | |
| Total current liabilities | 17 | — | 16 | 26 | — | |
| Total liabilities | 17 | — | 16 | 26 | — | |
| Commitments and contingencies (Note 8) | — | — | — | — | — | |
| Preferred stock, par value $0.001; authorized shares - 10,000,000; issued and outstanding shares - none | 0 | — | 0 | 0 | — | |
| Common stock, par value $0.001; authorized shares - 100,000,000; issued and outstanding shares - 59,440,045 and 48,936,459 at December 31, 2025 and 2024, respectively | 59,000 | — | 49,000 | 41,000 | 165 | |
| Additional paid-in capital | 806 | — | 553 | 400 | — | |
| Accumulated other comprehensive income | 334,000 | — | 55,000 | 141,000 | — | |
| Accumulated deficit | −347 | — | −243 | −154 | — | |
| Total stockholders' equity | 460 | — | 310 | 246 | — | |
| Total liabilities and stockholders' equity | 476 | — | 326 | 272 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation | 263,000 | 317,000 | 297,000 | 215,000 | 100,000 | |
| Stock-based compensation | 34 | 20 | 13 | 3 | 4 | |
| Non-cash lease expense | 353,000 | 320,000 | 306,000 | 0 | — | |
| Amortization of premiums and discounts on marketable securities, net | −227,000 | 424,000 | −5 | 0 | 155,000 | |
| Loss on disposal of property and equipment | 106,000 | 11,000 | — | — | — | |
| Prepaid expenses, other current and long-term assets | −1 | −5 | −4 | −2 | −235,000 | |
| Operating lease liabilities | −337,000 | −335,000 | −310,000 | 4,000 | — | |
| Accounts payable | 817,000 | 810,000 | −2 | 411,000 | 389,000 | |
| Accrued expenses and other liabilities | −496,000 | −248,000 | 8 | 2 | 393,000 | |
| Net cash used in operating activities | −70 | −73 | −61 | −32 | −47 | |
| Maturities of marketable securities | 273 | 314 | 120 | 0 | — | |
| Purchases of marketable securities | −447 | −351 | −268 | 0 | — | |
| Receipt of contingent value right milestone | 0 | 10 | 0 | — | — | |
| Payment of contingent value right milestone, net of permitted deductions | 0 | −9 | 0 | — | — | |
| Purchases of property and equipment | −158,000 | −44,000 | −149,000 | −612,000 | −12,000 | |
| Proceeds from sale of property and equipment | 213,000 | 0 | — | — | — | |
| Net cash used in investing activities | −174 | −36 | −148 | −612,000 | −2 | |
| Proceeds from exercise of stock options | 2 | 4 | 399,000 | 591,000 | 860,000 | |
| Proceeds from issuance of common stock under the Employee Stock Purchase Plan | 620,000 | 651,000 | 0 | — | — | |
| Proceeds from issuance of common stock and pre-funded warrants in the Public Offering, net of issuance costs | 216 | 0 | — | — | — | |
| Proceeds from issuance of common stock and Pre-Funded Warrants in the Private Placement, net of issuance costs | 0 | 90 | 0 | — | — | |
| Proceeds from issuance of common stock under the Sales Agreement, net of issuance costs | 0 | 39 | 0 | — | — | |
| Payment of deferred offering costs | −217,000 | 0 | — | — | — | |
| Net cash provided by financing activities | 219 | 133 | 234 | −2 | 49 | |
| Net (decrease) increase in cash, cash equivalents and restricted cash | −25 | 24 | 25 | −34 | 698,000 | |
| Income taxes paid related to the contingent value right milestone | 0 | 232,000 | 0 | — | — | |
| Operating lease right-of-use assets obtained in exchange for operating lease liabilities | 736,000 | 0 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Enliven Therapeutics, Inc.'s CIK number?
Enliven Therapeutics, Inc.'s SEC CIK number is 0001672619 (1672619). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Enliven Therapeutics, Inc.'s SEC filings?
All of Enliven Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Enliven Therapeutics, Inc. last report earnings?
Enliven Therapeutics, Inc. (ELVN) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-211921). This is Enliven Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Enliven Therapeutics, Inc.'s most recent earnings 8-K?
Enliven Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001193125-26-211921. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Enliven Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →